secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001628280-26-029524
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028
--------------------------------------------------------------------------------

- Net product revenue $20.0M (up 15% YoY from $17.4M).
- Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).
- Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.
- LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/0001628280-26-029524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828026029524/adc-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-029524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer